These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 7786781)

  • 41. Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups.
    Bassan R; Chiodini B; Lerede T; Giussani U; Oldani E; Buelli M; Rossi A; Viero P; Rambaldi A; Barbui T
    Hematol J; 2002; 3(4):193-200. PubMed ID: 12189565
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
    Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cyclosporin increases cellular idarubicin and idarubicinol concentrations in relapsed or refractory AML mainly due to reduced systemic clearance.
    Smeets M; Raymakers R; Muus P; Vierwinden G; Linssen P; Masereeuw R; de Witte T
    Leukemia; 2001 Jan; 15(1):80-8. PubMed ID: 11243404
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Feasibility and results of autologous stem cell transplantation in de novo acute myeloid leukemia in patients over 60 years old. Results of the CETLAM AML-99 protocol.
    Oriol A; Ribera JM; Esteve J; Guàrdia R; Brunet S; Bueno J; Pedro C; Llorente A; Tormo M; Besalduch J; Sánchez JM; Batlle M; Vivancos P; Carreras E; Vilà JM; Julià A; Sierra J; Montserrat E; Feliu E;
    Haematologica; 2004 Jul; 89(7):791-800. PubMed ID: 15257930
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Acute myeloid leukemia with poor prognosis: treatment with oral 4-demethoxydaunorubicin (idarubicin) and low-dose cytarabine via subcutaneous route].
    Helg C; Chapuis B; Grob JP; Pugin P
    Schweiz Med Wochenschr; 1990 Apr; 120(15):548-52. PubMed ID: 2336558
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study.
    Juliusson G; Höglund M; Karlsson K; Löfgren C; Möllgård L; Paul C; Tidefelt U; Björkholm M;
    Br J Haematol; 2003 Dec; 123(5):810-8. PubMed ID: 14632771
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
    Guolo F; Minetto P; Clavio M; Miglino M; Di Grazia C; Ballerini F; Pastori G; Guardo D; Colombo N; Kunkl A; Fugazza G; Rebesco B; Sessarego M; Lemoli RM; Bacigalupo A; Gobbi M
    Am J Hematol; 2016 Aug; 91(8):755-62. PubMed ID: 27084986
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
    Shen Y; Chen J; Liu Y; Wu D
    Chemotherapy; 2014; 60(5-6):368-74. PubMed ID: 26496511
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The treatment of acute myeloid leukemia with mitoxantrone, etoposide and low-dose cytarabine in elderly patients - a report of Polish Acute Leukemia Group (PALG) phase II study.
    Wrzesien-Kus A; Robak T; Jamroziak K; Wierzbowska A; Dmoszynska A; Adamczyk-Cioch M; Kuliczkowski K; Mazur G; Holowiecki J; Konopka L; Maj S; Marianska B; Zawilska K;
    Neoplasma; 2002; 49(6):405-11. PubMed ID: 12584589
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Treating patients with acute myeloid leukemias (AML) according to the protocol of the AML-01.10 Russian multicenter randomized trial: the coordinating center's results].
    Parovichnikova EN; Troitskaia VV; Kliasova GA; Kuz'mina LA; Sokolov AN; Paramonova EV; Galstian GM; Kessel'man SA; Drokov MIu; Vasil'eva VA; Obukhova TN; Kulikov SM; Savchenko VG
    Ter Arkh; 2014; 86(7):14-23. PubMed ID: 25314773
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Idarubicin in the therapy of acute myeloid leukemia: final analysis in 57 previously untreated patients.
    Lambertenghi Deliliers G; Annaloro C; Oriani A; Pozzoli E; Cortelezzi A; Cortellaro M; Mozzana R; Della Volpe A; Soligo D; Cofrancesco E
    Semin Oncol; 1993 Dec; 20(6 Suppl 8):27-33. PubMed ID: 8290969
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased myelotoxicity of idarubicin: is there a pharmacological basis? Results of a pharmacokinetic and an in vitro cytotoxicity study.
    Kroschinsky F; Schleyer E; Renner U; Schimming C; Schimmelpfennig C; Bornhäuser M; Illmer T; Trümper L; Ehninger G; Schaich M
    Cancer Chemother Pharmacol; 2004 Jan; 53(1):61-7. PubMed ID: 12955471
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75.
    Reiffers J; Huguet F; Stoppa AM; Molina L; Marit G; Attal M; Gastaut JA; Michallet M; Lepeu G; Broustet A; Pris J; Maraninchi D; Hollard D; Fabères C; Mercier M; Hurteloup P; Danel P; Tellier Z; Berthaud P
    Leukemia; 1996 Mar; 10(3):389-95. PubMed ID: 8642852
    [TBL] [Abstract][Full Text] [Related]  

  • 54. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
    Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
    J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001.
    Alymara V; Tzouvara E; Vartholomatos G; Chaidos A; Tsiara S; Bourantas KL
    J Exp Clin Cancer Res; 2004 Sep; 23(3):447-54. PubMed ID: 15595635
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
    J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group.
    Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R
    J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A phase I/II study of oral etoposide and idarubicin in elderly patients with high-risk acute myeloid leukemia unable to undergo intensive chemotherapy.
    Fiegl M; Büchner T; Hiddemann W; Braess J
    Ann Hematol; 2005 Apr; 84(4):227-31. PubMed ID: 15517268
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Standard-dose of idarubicin in combination with continuous infusion of cytarabine as induction therapy in patients with acute myeloid leukaemia].
    Qian SX; Li JY; Wu HX; Lu H; Qiu HX; Chen LJ; Lu RN; Xu W; Sheng RL
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):209-13. PubMed ID: 19236781
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia.
    Horácek JM; Pudil R; Tichý M; Jebavý L; Strasová A; Praus R; Zák P; Malý J
    Neoplasma; 2005; 52(5):430-4. PubMed ID: 16151589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.